治疗性DNA疫苗 向 Mycobacterium 结核病 持久 缩短 治愈性结核病治疗
bioRxiv : the preprint server for biology
|September 16, 2024
概括
一种针对Mycobacterium tuberculosis (Mtb) 的新型鼻内DNA疫苗缩短了小鼠肺结核 (TB) 治疗的时间. 这种治疗性结核病疫苗增强了免疫反应,在非人类灵长类动物中显示出有前途,可能有助于临床开发.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 传染性疾病 传染性疾病
背景情况:
- 由Mycobacterium tuberculosis (Mtb) 引起的结核病 (TB) 仍然是全球领先的传染病杀手.
- 迫切需要治疗性疫苗来缩短结核病治疗时间和预防复发.
- 目前治疗疫苗的选择有限,这突出了需要新的策略.
研究的目的:
- 评估一种新的鼻内DNA疫苗作为结核病的辅助疗法.
- 评估疫苗在小鼠模型中缩短治疗药物治疗的能力.
- 在非人类灵长类动物中研究疫苗的免疫性和疗效.
主要方法:
- 开发一种内DNA疫苗,将Mtb rel基因与MIP-3α/CCL融合.
- 给接受结核病治疗的免疫能力较强的小鼠注射疫苗.
- 评估Mtb特异性T细胞反应,树突细胞的招募和激活以及结核病控制.
- 在CD4+淘汰赛小鼠和非人类灵长类动物中对疫苗的评估.
主要成果:
- 鼻内DNA疫苗显著缩短了小鼠治疗结核病的治疗时间.
- 接种疫苗在各种组织和BAL液中增强了持续的Mtb特异性T细胞反应.
- 该疫苗促进了树突细胞的招募和激活,改善了先天适应性免疫交叉交互.
- 该疫苗增强了耐药结核病疗法,并在CD4+淘汰赛小鼠中显示出有效性.
- 在非人类灵长类动物中证实了免疫性,反应类似于受保护的小鼠.
结论:
- 新型融合DNA疫苗是一个有前途的治疗结核病疫苗候选人.
- 它有效地缩短了结核病治疗,通过引起强大和持续的保护性免疫反应.
- 该疫苗在包括非人类灵长类动物在内的各种模型中的有效性支持其临床开发潜力.
相关概念视频
Pulmonary Tuberculosis V
172
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
172
Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis II
214
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
214
Pulmonary Tuberculosis I
225
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
225
Pulmonary Tuberculosis III
313
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
313


